SCHEDULE 13G/A: RA Capital Management and Affiliates Disclose 4.7% Passive Stake in EyePoint Pharmaceuticals

RA Capital Management, along with its affiliates Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has filed an amendment to their Schedule 13G, disclosing a 4.7% beneficial ownership stake in EyePoint Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 3 to their Schedule 13G.
• The filing pertains to their beneficial ownership of Common Stock, par value $0.001 per share, of EyePoint Pharmaceuticals, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially owned 3,181,818 shares of EyePoint Pharmaceuticals, Inc. Common Stock.
• This ownership represents 4.7% of the issuer's outstanding Common Stock.
• The percentage is based on 68,251,031 shares outstanding as of October 31, 2024, as reported in EyePoint Pharmaceuticals' Quarterly Report on Form 10-Q filed on November 7, 2024.
• The shares are directly held by RA Capital Healthcare Fund, L.P., with RA Capital Management, L.P. serving as investment adviser, and Peter Kolchinsky and Rajeev Shah as controlling persons of RA Capital Management GP, LLC.
• The Reporting Persons expressly disclaim status as a "group" for Schedule 13G purposes and certify that the shares were not acquired to change or influence control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership. It does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or prospects. The disclaimers are standard for this type of filing.

Risks

• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G, which is a legal clarification to avoid certain regulatory implications.
• RA Capital Healthcare Fund, L.P. disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act, due to delegating voting and investment power to RA Capital Management, L.P. with less than 61 days' notice for revocation.
• RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of the reported securities for any purpose other than determining their obligations under Section 13(d) of the Act.

Future Outlook

NA

Industry Context

This filing indicates continued passive investment by a specialized healthcare fund (RA Capital) in a biotechnology/pharmaceutical company (EyePoint Pharmaceuticals). Such filings are routine disclosures for significant passive stakes in the highly dynamic and capital-intensive pharmaceutical industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company, which can influence investor perception and liquidity.

Key Dates

Keywords

EyePoint Pharmaceuticals, RA Capital Management, RA Capital Healthcare Fund, Peter Kolchinsky, Rajeev Shah, Schedule 13G/A, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing